BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

The Swedish firm has treated the first two patients in a Phase I/II trial of the autologous neoantigen-directed lymphocyte therapy.

The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.

The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.